Dr. Agostino Consoli, Italy

Prof.  Consoli is Professor of  Endocrinology at the University “G. d’Annunzio” School of Medicine in Chieti, Italy. Prof. Consoli received his M.D. degree from the University of Chieti, Italy (Summa cum laude). After a research fellowship in endocrine research at the Mayo Clinic, Rochester, MN, USA (1985 – 1987) he has been a Research Associate in the Clinical Research Center of the University of Pittsburgh, Pittsburgh, PA, USA  (1997 – 1990) and then an Assistant Professor in the Diabetes  Division at the University of Texas Health Science Center at San Antonio, TX, USA. Since  2001 until 2013 he has been in charge of the Diabetes Clinic at the Pescara Town Hospital in Pescara, Italy and He is presently the Head of the Endocrine and Metabolism Unit at the same institution. He is also the Director of the University of Chieti Center for Ageing Sciences and Translational Medicine and the Head of the Clinical Research Center at the University “G. d’Annunzio” Foundation in Chieti. At the University of Chieti, Prof Consoli is the Coordinator of the PhD Program in Translational Medicine and the Director of the Specialty School in Endocrinology 
Prof Consoli is member of prestigious Societies, including the American Diabetes Association, the American Society of Clinical Physiology and the European Association for the Study of Diabetes. He has served as  a member of the National Council of the Italian Society of Diabetologia and as coordinator of the National Scientific Committee. He is presently the National Coordinator of the Study Center of the Italian Diabetes Society.  Prof Consoli is an established reviewer for several international peer-review journals, including American Journal of Physiology, Diabetes, Diabetologia, Journal of Clinical Investigation, Circulation and Atherosclerosis Thrombosis and Vascular Biology; he serves on the Editorial Board of the Journal of Diabetes and Its Complications. Dr Consoli has authored or co-authored over 150 original research articles and 14 book chapters. His work has received so far over 5,000 citations.
He and his coworkers are actively involved in researches on glucose metabolism, pathogenesis of type 2 diabetes, insulin resistance and macrovascular complications of diabetes. His most recent work has focused on  the relationships between hyperglycemia, insulin resistance and endothelial dysfunction as well as on innovative therapeutic strategies for type 2 diabetes.  He has been and he is presently involved as a Co-Investigator or as a Principal Investigator in over 50 major Clinical Trials on new molecules for the treatment of Type 2 Diabetes.